RVPH · Reviva Pharmaceuticals Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.44M | - | $2.13M | $3.72M | $4.11M | - | $6.86M | $5.58M | $5.78M | - |
| SG&A | $1.84M | - | $1.90M | $2.35M | $2.42M | - | $1.60M | $2.55M | $2.14M | - |
| Total Operating Expenses | $3.27M | - | $4.03M | $6.07M | $6.54M | - | $8.46M | $8.13M | $7.92M | - |
| D&A | - | - | - | - | - | - | - | - | $0 | - |
| Operating Income | ($3.27M) | - | ($4.03M) | ($6.07M) | ($6.54M) | - | ($8.46M) | ($8.13M) | ($7.92M) | - |
| Interest Expense | $6.7K | - | $2.6K | $4.8K | $3.5K | - | $5.1K | $12.8K | $3.5K | - |
| Income Tax | $3.3K | - | $2.8K | $8.0K | $5.2K | - | $0 | $7.4K | $7.4K | - |
| Net Income | ($3.20M) | - | ($4.01M) | ($6.05M) | ($6.43M) | - | ($8.37M) | ($7.86M) | ($7.43M) | - |
| EPS - Basic | ($0.46) | - | ($1.20) | ($2.40) | ($2.60) | - | ($5.00) | ($5.20) | ($5.00) | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.19M | $14.44M | $13.18M | $10.36M | $5.29M | $13.48M | $5.56M | $6.18M | $11.97M | $23.37M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.09M | $3.01M | $5.43M | $4.97M | $4.72M | $6.28M | $8.78M | $4.69M | $5.72M | $3.85M |
| Current Assets | $23.56M | $15.10M | $13.51M | $10.82M | $6.26M | $14.68M | $6.81M | $7.23M | - | - |
| Total Assets | $23.56M | $15.92M | $14.33M | $11.63M | $7.08M | $15.50M | $7.63M | $8.05M | $13.50M | $23.70M |
| Current Liabilities | $6.12M | $7.28M | $9.74M | $12.08M | $11.51M | $14.60M | $17.53M | $13.94M | $14.49M | $17.18M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.12M | $7.28M | $9.78M | $12.09M | $11.54M | $14.69M | $17.61M | $14.09M | $14.84M | $17.98M |
| Stockholders' Equity | $17.44M | $8.65M | $4.55M | ($459.1K) | ($4.46M) | $812.6K | ($9.98M) | ($6.04M) | ($1.35M) | $5.72M |
| Retained Earnings | ($187.33M) | ($184.14M) | ($180.77M) | ($176.76M) | ($170.71M) | ($164.27M) | ($158.01M) | ($149.65M) | ($141.79M) | ($134.35M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.80M) | - | - | - | ($8.19M) | - | - | - | ($11.73M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $11.55M | - | - | - | $7.3K | - | - | - | $332.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -13.6% | - | -28.0% | -52.0% | -90.9% | - | -109.6% | -97.6% | -55.1% | - |
| Return on equity | -18.3% | - | -88.2% | 1318.4% | 144.2% | - | 83.8% | 130.1% | 552.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.85 | 2.08 | 1.39 | 0.90 | 0.54 | 1.01 | 0.39 | 0.52 | - | - |
| Quick ratio | 3.85 | 2.08 | 1.39 | 0.90 | 0.54 | 1.01 | 0.39 | 0.52 | - | - |
| Cash ratio | 3.63 | 1.98 | 1.35 | 0.86 | 0.46 | 0.92 | 0.32 | 0.44 | 0.83 | 1.36 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -491.8x | - | -1547.0x | -1266.0x | -1875.0x | - | -1644.5x | -637.2x | -2271.9x | - |
| Equity multiplier | 1.35 | 1.84 | 3.15 | -25.34 | -1.59 | 19.08 | -0.76 | -1.33 | -10.03 | 4.14 |
| Liabilities / Assets | 0.26 | 0.46 | 0.68 | 1.04 | 1.63 | 0.95 | 2.31 | 1.75 | 1.10 | 0.76 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 50.0% | - | 52.4% | 25.3% | 17.5% | - | 21.0% | 32.6% | -17.6% | - |
| Net income growth (YoY) | 50.3% | - | 52.1% | 23.0% | 13.5% | - | 20.3% | 36.8% | -12.6% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 964.2% | - | 92.4% | -231.4% | -85.8% | -17.2% | - | - | -53.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing REVIVA PHARMACEUTICALS HOLDINGS against the 5 most active filers in the same SIC group.